Faculty
Doug Adkins.jpg

Douglas R. Adkins, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Head and neck cancer
  • Sarcoma
  • Thyroid cancer

Contact

  • 314-747-8475 (tel)
  • 314-362-7086 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Letters

  • RTOG 0522: Huge investment in patients and resources and no benefit with addition of cetuximab to radiotherapy - why did this occur?
    Adkins D, Ley J, Wildes TM, Michel L
    J Clin Oncol 2015 Apr 1;33(10):1223-4
  • Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit
    Adkins D, Ley J, Michel L, Wildes TM, Thorstad W, Rich J, Nussenbaum B
    Oral Oncol 2015 Feb;51(2):103-4
  • Re: High rate of graft failure in 25 patients with chronic myelogenous leukemia conditioned with a reduced-intensity regimen of 550 cGy total body irradiation and cyclophosphamide for unrelated donor transplantation
    Hallemeier C, Girgis M, Khoury H, Devine S, Blum W, Vij R, Lin HS, DiPersio J, Adkins DR
    Biol Blood Marrow Transplant 2004 Oct;10(10):726-7
  • Unstable angina in a peripheral blood stem and progenitor cell donor given granulocyte-colony-stimulating factor
    Vij R, Adkins DR, Brown RA, Khoury H, DiPersio JF, Goodnough T
    Transfusion 1999 May;39(5):542-3
  • Purine analog regimens for allogeneic transplant?
    Adkins D, Brown R, Goodnough L, Khoury H, DiPersio J
    J Clin Oncol 1999 Jun;17(6):1958-60
  • Anaphylactoid reaction in a normal donor given granulocyte colony- stimulating factor
    Adkins DR
    J Clin Oncol 1998 Feb;16(2):812-3
  • Patient selection in high-dose trials of breast cancer
    Adkins DR, Brown RA, DiPersio JF
    J Clin Oncol 1998 Mar;16(3):1238-9
  • Granulocyte-macrophage colony-stimulating factor with induction treatment of acute myelogenous
    Adkins DR, Brown RA, DiPersio JF
    J Clin Oncol 1997 Feb;15(2):862-3

Invited Publications

  • Head and neck cancer
    Adkins D, Michel L, Wildes T, Ley J, Thorstad W, Nussenbaum B
    In: The Washington Manual of Oncology, Third Edition. 2015. ed. Govindan R.
  • Sarcomas
    Adkins D, Van Tine BA, Rachocki TB
    In: Devita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology Review, 3rd Edition, Govindan R (ed). Chapter 26:365-374. Lippincott Williams & Wilkins 2012
  • Sarcoma
    Adkins DR
    In: Devita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology Review, 2nd Edition, Govindan R (ed) 2009
  • Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?
    Adkins DR, DiPersio JF
    Curr Opin Hematol 2008 Nov;15(6):555-60
  • Reduced-intensity conditioneing for allogeneic hematopoietic stem cell transplantation
    Khoury HJ, Adkins DR
    In: Hematopoietic Stem Cell Transplantation in Clinical Practice. Treleaven J, Barrett AJ (eds). Chapter 28: 287-291. Elsevier 2008
  • Sarcoma
    Kuperman D, Adkins D
    In: The Washington Manual of Oncology, Second Edition. 2008. ed. Govindan R.
  • Head and neck cancer
    Kuperman D, Arquette M, Adkins D
    In: The Washington Manual of Oncology, Second Edition. 2008. ed. Govindan R.
  • High-dose therapy for primary and metastatic breast cancer
    Spitzer G, Meehan K, Adkins D
    In:Hematopoietic Stem Cell Transplantation. July 2000, eds. Ho AD, Haas R, and Champlin RE, Marcel Dekker, Inc., New York, NY
  • Use of filgrastim (r-metHuG-CSF) in neutrophil transfusions
    Adkins DR, Brown R, Goodnough T, DiPersio J
    In: Filgrastim (R-metHuG-CSF) in Clinical Practice, Second Edition. pp. 149-164.,1998, eds. Morstyn G and Dexter M, Marcel Dekker, Inc., New York, NY
  • Peripheral blood stem cells: Possibilities and limitations
    Spitzer G, Adkins DR, Burger S
    Hematopoietic Stem Cells: Biology and Therapeutic Applications, Marcel Dekker, Inc. New York, NY, eds: Levitt D, Mertelsmann R, February 1995
  • Hematopoietic growth factors: A review
    Adkins DR, Spitzer G
    Resident and Staff Physician, January 1995
  • Peripheral blood stem cells: Possibilities and limitations
    Spitzer G, Burger S, Adkins DR
    In Hematopoietic Stem Cells: Biology and Therapeutic Applications Eds: Levitt/Mertelsmann, Chapter 20, pp. 391-401
  • Progenitor assays, how much and when?
    Spitzer G, Kulkarni S, Kronmueller N, Adkins DR
    Am Assoc of Blood Banks: Marrow and Stem Cell Processing for Transplantation. Lasky L and Warkentin P, eds; Chapter 2, pp. 21-34, 1994
  • Filgrastim (r-metHuG-CSF) in bone marrow and peripheral blood cell transplantation
    Spitzer G, Dunphy FR II, Velasquez WS, Petruska PJ, Adkins DR
    In: Morstyn G, Dexter TM, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice. New York: Marcel Dekker; 173-195, 1993
  • Studies to eliminate the absolute neutropenia of high-dose chemotherapy
    Spitzer G, Dunphy F, Adkins DR, Petruska P, Velasquez W
    Proceedings of the Second Consensus Development Conference on the Treatment of Radiation Injuries, Armed Forces Radiobiology Research Institute, Bethesda, MD, April 1993. Advances in the Treatment of Radiation Injuries, Edited by T.J. MacVittie, J.F. Weiss, D. Browne in the series "Advances in the Biosciences" (Pergamon, Elsevier Science)
  • Text of biochemical terminology
    Adkins DR, DeBold LA, Bair DK, Organisciak DT
    Wright State University School of Medicine, Dayton, Ohio, 1983